Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

REVENUES, NET (Tables)

REVENUES, NET (Tables)

3 Months Ended

Mar. 31, 2022

Revenue From Contract With Customer [Abstract]

Summary of revenues, net disaggregated by category

Revenues, net disaggregated by category, were as follows (in thousands):

	Three Months Ended March 31,
	2022		2021
Endari®	$	3,048	$	5,176
Other		186	$	159
Revenues, net	$	3,234	$	5,335

Revenue Allowance and Accrual Activities

The following table summarizes the revenue allowance and accrual activities for the three months ended March 31, 2022 and March 31, 2021 (in thousands):

	Trade Discounts, Allowances and Chargebacks			Government Rebates and Other Incentives			Returns			Total
Balance as of December 31, 2021	$	1,480		$	3,134		$	540		$	5,154
Provision related to sales in the current year		428			435			30			893
Adjustments related prior period sales		(10	)		13			(47	)		(44	)
Credit and payments made		(1,064	)		(453	)		(32	)		(1,549	)
Balance as of March 31, 2022	$	834		$	3,129		$	491		$	4,454

Balance as of December 31, 2020	$	134		$	2,119		$	473		$	2,726
Provision related to sales in the current year		575			864			57			1,496
Adjustments related prior period sales		14			2			(37	)		(21	)
Credit and payments made		(281	)		(792	)		—			(1,073	)
Balance as of March 31, 2021	$	442		$	2,193		$	493		$	3,128

Summarizes net revenues from each of our customers accounted for 10% or more of net revenues

The following table summarizes net revenues attributable to each of our customers that accounted for 10% or more of net revenues (as a percentage of net revenues) during the periods presented:

	Three Months Ended March 31,
	2022			2021
Customer A		1	%		63	%
Customer B		46	%		17	%
Customer C		15	%		9	%
Customer D		16	%	—
Total		78	%		89	%